Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Townsend

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Leukemia & Lymphoma|February 9, 2023
Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphomaHoa Van Le, Kim Van Naarden Braun, Grzegorz S Nowakowski, et al.
The New England Journal of Medicine|October 5, 2017
Obinutuzumab for the First-Line Treatment of Follicular LymphomaRobert Marcus, Andrew Davies, Kiyoshi Ando, et al.
Blood Advances|February 1, 2023
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphomaClaire Roddie, Lorna Neill, Wendy Osborne, et al.
Blood|November 19, 2020
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphomaMehdi Hamadani, John Radford, Carmelo Carlo-Stella, et al.
The Lancet. Haematology|April 30, 2025
Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trialMichael Northend, William Wilson, Kushani Ediriwickrema, et al.
Blood Advances|August 30, 2024
Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party studySimon Renders, Maud Ngoya, Herve Finel, et al.
Journal of Public Health in Africa|August 4, 2023
Tackling antimicrobial resistance: developing and implementing antimicrobial stewardship interventions in four African commonwealth countries through a health partnership modelDiane Ashiru-Oredope, Maxencia Nabiryo, Lisa Zengeni, et al.
Hemasphere|July 5, 2023
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM StudyWilliam Townsend, Wolfgang Hiddemann, Christian Buske, et al.
Hemasphere|December 13, 2021
A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory LymphomaGraham P Collins, Toby A Eyre, Debora Schmitz-Rohmer, et al.
Blood Advances|November 15, 2023
Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experienceRohan Shotton, Rachel Broadbent, Alia Alchawaf, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Leukemia & Lymphoma|February 9, 2023
Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphomaHoa Van Le, Kim Van Naarden Braun, Grzegorz S Nowakowski, et al.
The New England Journal of Medicine|October 5, 2017
Obinutuzumab for the First-Line Treatment of Follicular LymphomaRobert Marcus, Andrew Davies, Kiyoshi Ando, et al.
Blood Advances|February 1, 2023
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphomaClaire Roddie, Lorna Neill, Wendy Osborne, et al.
Blood|November 19, 2020
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphomaMehdi Hamadani, John Radford, Carmelo Carlo-Stella, et al.
The Lancet. Haematology|April 30, 2025
Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trialMichael Northend, William Wilson, Kushani Ediriwickrema, et al.
Blood Advances|August 30, 2024
Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party studySimon Renders, Maud Ngoya, Herve Finel, et al.
Journal of Public Health in Africa|August 4, 2023
Tackling antimicrobial resistance: developing and implementing antimicrobial stewardship interventions in four African commonwealth countries through a health partnership modelDiane Ashiru-Oredope, Maxencia Nabiryo, Lisa Zengeni, et al.
Hemasphere|July 5, 2023
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM StudyWilliam Townsend, Wolfgang Hiddemann, Christian Buske, et al.
Hemasphere|December 13, 2021
A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory LymphomaGraham P Collins, Toby A Eyre, Debora Schmitz-Rohmer, et al.
Blood Advances|November 15, 2023
Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experienceRohan Shotton, Rachel Broadbent, Alia Alchawaf, et al.
Pageof 6